



Foundation Medicine to Launch Hereditary Germline Tests, FoundationOne®Germline and FoundationOne®Germline More, in the United States Through a Partnership with Fulgent Genetics

February 4, 2025

BOSTON & EL MONTE, CALIF., February 4, 2025 - [Foundation Medicine, Inc.](#), a genomics company committed to transforming cancer care, today announced plans to launch two new germline tests, FoundationOne®Germline and FoundationOne®Germline More, in the United States to identify genetic variants associated with hereditary cancers and can be used by healthcare providers to understand underlying risks for patients and their families. These tests will be offered through a partnership with Fulgent Genetics, Inc. (NASDAQ: FLGT) ("Fulgent"). The companies are planning for healthcare providers to be able to add FoundationOne Germline or FoundationOne Germline More to any Foundation Medicine comprehensive genomic profiling test, through Foundation Medicine's portal beginning February 28, 2025.

FoundationOne Germline is a next-generation sequencing (NGS) test that analyzes 50 genes associated with hereditary cancers. It is suitable for individuals with a personal or family history indicative of hereditary cancers. FoundationOne Germline More is an expanded NGS panel analyzing 154 genes, including well-established cancer-related genes and candidate genes with emerging evidence of association with cancer risk. It is intended for individuals with complex clinical presentations and family histories requiring broader genetic analysis.

"Healthcare providers have many factors to consider when making treatment decisions, and we are always looking to bring additional solutions to the market to provide as much information as possible," said Annie Murphy, chief commercial officer at Foundation Medicine. "The results from our germline tests can help explain why a patient initially developed cancer and provide insights into potential increased future cancer risks, delivering important new value to the healthcare providers and patients we serve."

Both tests are powered by Fulgent's proprietary technology platform and analyze single nucleotide and copy number variations. When combined with Foundation Medicine's comprehensive genomic profiling (CGP) tests, FoundationOne®CDx, FoundationOne®Liquid CDx, FoundationOne®Heme and FoundationOne®RNA, germline testing supports healthcare providers in building a more comprehensive molecular profile for their patients.

"There is no doubt the time has come to pair germline and somatic testing, and this new partnership brings together two companies that are exceedingly strong in each," said Brandon Perthuis, chief commercial officer at Fulgent. "We are very excited to bring this offering to oncologists in partnership with Foundation Medicine, and we look forward to a strong collaboration with a mutual goal of advancing patient care."

Foundation Medicine and FoundationOne® are registered trademarks of Foundation Medicine, Inc.

About Foundation Medicine: Your Essential Partner in Cancer Care

Foundation Medicine is a pioneer in molecular profiling for cancer, working to shape the future of clinical care and research. We collaborate with a broad range of partners across the cancer community and strive to set the standard for quality, scientific excellence, and regulatory leadership. Our deep understanding of cancer biology helps physicians make informed treatment decisions for their patients and empowers researchers to develop new medicines. Every day, we are driven to help our partners find answers and take action, enabling more people around the world to benefit from precision cancer care. For more information, please visit us on www.FoundationMedicine.com and follow us on [LinkedIn](#) and [X](#).

About Fulgent

Fulgent is a technology-based company with a well-established laboratory services business and a therapeutic development business. Fulgent's laboratory services business, which was formerly referred to as the clinical diagnostic business, includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Fulgent's therapeutic development business is focused on developing drug candidates for treating a broad range of cancers using a novel nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The Company aims to transform from a genomic diagnostic business into a fully integrated precision medicine company.

Media Contact:

Foundation Medicine:

Holly Campbell, 480-213-8368

newsroom@foundationmedicine.com